Market Overview

Kerrisdale Capital Short Zafgen With $3 Price Target, Says Obesity Drug Has 'No Reasonable Chance' Of FDA Approval

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for ZFGN

DateFirmActionFromTo
Jan 2017JMP SecuritiesUpgradesMarket PerformMarket Outperform
Jul 2016Cowen & Co.DowngradesOutperformMarket Perform
Jul 2016FBR CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for ZFGN
View the Latest Analyst Ratings

Posted-In: Analyst Color News Analyst Ratings

 

Related Articles (ZFGN)